Main Article Content
Background: COVID-19 vaccination is the administration of a vaccine to help the individuals to protect from COVID-19. COVID-19 vaccines have been unfurled in several parts of the world. Although the protective efficacy was frequently discussed and analysed, little is known about post-vaccination experience outside of clinical trial conditions. The aim of the study was symptoms following COVID-19 vaccination in selected area, Puducherry, with the objectives of to assess the immediate response to the first dose of COVID-19 vaccine and to study the spectrum of post-vaccination symptom profile for individual vaccines.
Methodology: Quantitative approach and non-experimental cross-sectional design was used. The study was conducted in selected areas in Puducherry. 30 subjects were recruited by using convenience sampling technique. Demographic variable questionnaire and self-developed binary tools was used.
Results: The study results revealed that the Overall, all 30(100%) of respondents reported at least one post-vaccination symptom. 9(30%) had the symptoms of body ache, 7(23.3%) had fever, 6(20%) had local pain at injection site, 5(16.7%) had tiredness and 3(10%). Among male 10(33.3%) had paracetamol intake, 3(10%) had symptoms following vaccine, 4(13.3%) had symptoms within duration of hours and only 1(3.3%) had symptoms after onset in hours. Among female 10(33.3%) had taken paracetamol, 9(30%) had symptoms following vaccine, 7(23.4%) had symptoms within duration of hours and only 4(13.4%) had symptoms after onset in hours.
Conclusion: Body ache and fever was most commonly reported. These symptoms were consistent with an immune response commonly associated with vaccines. In 90% cases, the symptoms were either milder than expected or meeting the expectation of the vaccine recipient. No serious events were reported. Symptoms were more common among younger individuals.
World health organization (WHO), ENCES Modes of transmission of the virus causing COVID-19: implications for IPC precaution recommendation; 2020.
Vaccines and Related Biological Products Advisory Committee Meeting. FDA; 2020.
Mahase E. Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows.
Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
Wadman M. Public needs to prep for vaccine side effects; 2020.
Callaway E. Oxford covid vaccine results puzzle scientists. Nature; 2020
Sharma D, Covid-19: post-vaccine symptoms more common in young than elderly, says study; 2021.
Zeneca, one in four people experience mild side effects from Covishield vaccine: Lancet study; 2021.
RK Srivastava, The initial experience of COVID-19 vaccination from a tertiary care centre of India,
PMID: 33794595, DOI: 10.4081/monaldi.2021.1816
Michaud A, Cousens X, Sanchez B, Covid-19 Vaccine Experiences from Around the U.S; 2021.